Arecor Therapeutics plc (AREC.L)

GBp 38.0

(0.0%)

Market Cap (In GBp)

14.34 Million

Revenue (In GBp)

4.57 Million

Net Income (In GBp)

-8.55 Million

Avg. Volume

16.1 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
62.55-185.0
PE
-1.23
EPS
-0.31
Beta Value
-0.27
ISIN
GB00BMWLM973
CUSIP
-
CIK
-
Shares
37756600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sarah Jennifer Howell Ph.D.
Employee Count
-
Website
https://www.arecor.com
Ipo Date
2021-06-03
Details
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.